Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Assets (2016 - 2025)

Corcept Therapeutics' Assets history spans 10 years, with the latest figure at $836.7 million for Q4 2025.

  • For Q4 2025, Assets changed 0.46% year-over-year to $836.7 million; the TTM value through Dec 2025 reached $836.7 million, changed 0.46%, while the annual FY2025 figure was $836.7 million, 0.46% changed from the prior year.
  • Assets for Q4 2025 was $836.7 million at Corcept Therapeutics, up from $823.6 million in the prior quarter.
  • Across five years, Assets topped out at $846.5 million in Q1 2025 and bottomed at $423.8 million in Q4 2021.
  • The 5-year median for Assets is $594.0 million (2023), against an average of $639.9 million.
  • The largest annual shift saw Assets decreased 25.88% in 2021 before it soared 37.68% in 2022.
  • A 5-year view of Assets shows it stood at $423.8 million in 2021, then surged by 37.68% to $583.4 million in 2022, then rose by 6.53% to $621.5 million in 2023, then soared by 35.24% to $840.6 million in 2024, then fell by 0.46% to $836.7 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Assets are $836.7 million (Q4 2025), $823.6 million (Q3 2025), and $801.7 million (Q2 2025).